Today

Sinopharm to take control of Shandong Pharmaceutical Glass via USD 484m share placement

Shandong Pharmaceutical Glass published a prospectus on 9 October 2026 for a private placement of new A-shares raising up to USD 483.86m (CNY 3,235.12m) from China National Pharmaceutical International and Shandong Yaoxin Health Industry. On completion, China National Pharmaceutical International becomes controlling shareholder, its parent Sinopharm actual controller and the State Council's state assets commission ultimate controller, replacing the Yiyuan county finance bureau. The final share count requires Shanghai Stock Exchange approval and China Securities Regulatory Commission registration.

Why this mattersControl of a listed maker of pharmaceutical bottles, stoppers and caps passes from a county finance bureau to Sinopharm, bringing part of a drug group's packaging supply in-house.

  • After the placement, China National Pharmaceutical International becomes controlling shareholder, with Sinopharm as actual controller.
  • The placement raises up to USD 483.86m (CNY 3,235.12m) in cash.
  • Up to 199,084,233 new shares will be issued, capped at 30% of the pre-issue share count.
  • At the cap, the two subscribers would hold 23.08% of the enlarged share capital.
  • Current controlling shareholder Shandong Luzhong Investment holds 19.50%; the Yiyuan county finance bureau is actual controller.
  • Shandong Pharmaceutical Glass (SSE: 600529) makes pharmaceutical bottles, stoppers and caps.
Shandong Pharmaceutical Glass China National Pharmaceutical Group counterparty Shandong Yaoxin Health Industry counterparty
Relevant to you?

Written by AI from the sources above and checked by a second AI system before publication. No human wrote or edited this story. How it is made.

Updates

  • 2026-10-18 · Edited before publication: The headline gave a CNY amount without USD conversion. House style puts USD first with the original in brackets, at the precision of the source. 'Glass tubing' is not in the source, which names bottles, stoppers and caps. The 23.08% holding applies only if the issue is at its cap. Materiality is lowered to 3: the target is a followed company, not a core one.
  • 2026-10-18 · Edited before publication: Facts and conversion correct (CNY 3,235.12m / 6.686 = USD 483.86m). Summary ran to four sentences; condensed to three per house style.